Takeda, Japan's largest drugmaker, revealed plans to invest approximately 100 billion yen (~$769.3 million) to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan.
This represents Takeda’s largest ever investment in manufacturing capacity expansion in Japan.
The investment will enable Takeda to establish an end-to-end manufacturing facility for PDTs at its Juso, Osaka plant. The new site increases the capacity of Takeda’s current plasma manufacturing site in Narita, Japan almost five-fold and will enable Takeda to serve more patients in Japan, as well as add capacity to its global manufacturing network.
The plant will be fully integrated, comprising of teardown, fractionation, purification, filling and finishing capabilities as well as a cold storage warehouse. The design will be environmentally friendly to support Takeda's goal of achieving net-zero greenhouse gas emissions related to operations before 2035.
"The new facility will provide a plasma fractionation capacity of more than 2 million liters per year. The company will unleash the power of automation and digitalization to deliver high quality products to patients reliant on PDTs, including those with diseases for which there are no alternative treatments,” according to Thomas Wozniewski, global manufacturing & supply officer at Takeda.
The facility — which will be the largest of its kind in the country — is expected to be operational by around 2030.
